Business News • PR NewsWire • Nordic Nanovector: Safety Review Committee Approves Advancing to Final Dosing Regimen in Phase 1 Trial of Betalutin® in DLBCL

Nordic Nanovector: Safety Review Committee Approves Advancing to Final Dosing Regimen in Phase 1 Trial of Betalutin® in DLBCL

Nordic Nanovector: Safety Review Committee Approves Advancing to Final Dosing Regimen in Phase 1 Trial of Betalutin® in DLBCL

OSLO, Norway, April 10, 2019 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that the Safety Review Committee (SRC) for the ongoing LYMRIT 37-05 clinical trial of single-administration Betalutin® (177Lu-satetraxetan-lilotomab) in patients with relapsed/refractory diffuse large ...

View More : https://www.prnewswire.com:443/news-releases/nordic-nanovector-safety-review-committee-approves-advancing-to-final-dosin...

Releted News by prnewswire

NPI Hires Tara L. Kelly as Global Executive Assistant to Help Oversee Domestic and International Operations

Wirecard and Al Ansari Exchange Collaborate to Launch Enhanced Multi-currency Travel Card Solution

Diet Rich in Animal Protein is Associated With a Greater Risk of Death

Nordic Nanovector: Safety Review Committee Approves Advancing to Final Dosing Regimen in Phase 1 Trial of Betalutin® in DLBCL

Costar Technologies, Inc. Announces Delay in the Release of its Fourth Quarter and Full Year 2018 Results